dc.date.accessioned |
2021-06-04T08:06:06Z |
|
dc.date.available |
2021-06-04T08:06:06Z |
|
dc.date.issued |
2021 |
|
dc.identifier.issn |
1300-0144 |
|
dc.identifier.uri |
https://hdl.handle.net/20.500.12619/95617 |
|
dc.description |
We would like to thank the Sakarya Training and Research Hospital and the Infection Control Committee for their support in this research. This work has not received any funding. |
|
dc.description |
Bu yayının lisans anlaşması koşulları tam metin açık erişimine izin vermemektedir. |
|
dc.description.abstract |
Background/aim: The purpose of this study is to evaluate serum pentraxin-3 (PTX-3) levels in Sars-CoV-2 virus infection (COVID-19) patients and to investigate whether PTX-3 predicts the disease prognosis. Materials and methods: This study was conducted on 88 confirmed COVID-19 patients who were hospitalized due to symptomatic pneumonia between April 15 and August 15, 2020. The patients were divided into two groups as survived patients and non-survived patients. Both groups were compared according to demographic features, comorbid conditions and measurement of the PTX-3 and other laboratory parameters of the patients. Results: Of 88 patients with COVID-19, 59 (67%) were discharged with complete cure and 29 (33%) resulted in death. 46 (52.3%) of the patients were men. PTX-3 median value (IQR) was 3.66 ng/mL (0.9 & ndash;27.9) in all patients, 3.3 ng/mL (0.9 & ndash;27.9) in survivors and 3.91 ng/mL (1.9 & ndash;23.2) in nonsurvivors which was significantly higher (P = 0.045). As a receiver operating characteristic curve analysis the cut-off value of PTX-3 for predicting mortality in patients was 3.73 with 65% sensitivity and 65% specificity (AUC: 0.646, 95% CI: 0.525 & ndash; 0.767, P = 0.045). Also, we found significant cut-off values with respect to D-dimer, D-dimer/PTX-3, high-sensitivity troponin, high -sensitivity troponin/PTX-3, lymphocyte, PTX-3/lymphocyte, procalcitonin, procalcitonin/PTX-3, CRP, and CRP/PTX-3 (P < 0.05). Conclusion: In this study, as far as we know, for the first time, we have shown PTX-3 as the new mortality biomarker for COVID-19 disease. |
|
dc.description.sponsorship |
Sakarya Training and Research Hospital; Infection Control Committee |
|
dc.language |
English |
|
dc.language |
İngilizce |
|
dc.language.iso |
eng |
|
dc.publisher |
TUBITAK SCIENTIFIC & TECHNICAL RESEARCH COUNCIL TURKEY |
|
dc.rights |
info:eu-repo/semantics/closedAccess |
|
dc.title |
The predictive and diagnostic accuracy of long pentraxin-3 in COVID-19 pneumonia |
|
dc.type |
Article |
|
dc.contributor.authorID |
YAYLACI, SELCUK/0000-0002-6768-7973; kocayigit, havva/0000-0002-8719-7031; dheir, hamad/0000-0002-3569-6269; GENC, AHMED CIHAD/0000-0002-7725-707X; Issever, Kubilay/0000-0002-1376-1488 |
|
dc.contributor.authorID |
YAYLACI, SELCUK/0000-0002-6768-7973 |
|
dc.contributor.authorID |
kocayigit, havva/0000-0002-8719-7031 |
|
dc.identifier.volume |
51 |
|
dc.identifier.startpage |
448 |
|
dc.identifier.endpage |
453 |
|
dc.relation.journal |
TURKISH JOURNAL OF MEDICAL SCIENCES |
|
dc.identifier.issue |
2 |
|
dc.identifier.wos |
WOS:000646281600009 |
|
dc.identifier.doi |
10.3906/sag-2011-32 |
|
dc.identifier.eissn |
1303-6165 |
|
dc.contributor.author |
GENC, Ahmed Bilal |
|
dc.contributor.author |
YAYLACI, Selcuk |
|
dc.contributor.author |
DHEIR, Hamad |
|
dc.contributor.author |
GENC, Ahmed Cihad |
|
dc.contributor.author |
ISSEVER, Kubilay |
|
dc.contributor.author |
CEKIC, Deniz |
|
dc.contributor.author |
KOCAYIGIT, Havva |
|
dc.contributor.author |
COKLUK, Erdem |
|
dc.contributor.author |
KARACAN, Alper |
|
dc.contributor.author |
SEKEROGLU, Mehmet Ramazan |
|
dc.contributor.author |
CAKAR, Hande T. O. P. T. A. N. |
|
dc.contributor.author |
Guclu, Ertugrul |
|
dc.relation.publicationcategory |
Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı |
|
dc.identifier.pmıd |
33315349 |
|